BioSpace News Archive

iCAD, Inc. today announced the appointment of Dana Brown as Executive Chair of the Board of Directors.

Fresh Tracks Therapeutics, Inc. today announced publication of data from preclinical studies of FRTX-02, a potential first-in-class, orally bioavailable DYRK1A inhibitor, in the Journal of Translational Autoimmunity.

Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to provide the following business update for the first half of the 2023 financial year.

Visus Therapeutics Inc. today announced the appointment of Eric D. Donnenfeld, M.D., to the Company’s Board of Directors.

InvisiShield Technologies Ltd. today announced its Scientific Advisory Board (SAB) which is comprised of four experts in immunology and virology, including two Nobel Laureates.

XtalPi, Inc., a pioneering pharmaceutical technology company powered by artificial intelligence and automation, announced that Dr. Sarah Trice has joined the company as chief operating officer of U.S. operations.

Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2022 financial results ahead of its presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023.

AXIM Biotechnologies, Inc. announced that it has issued the following letter to its shareholders providing commentary on recent milestones achieved on its commercialized diagnostic solution platform and upcoming plans and goals for the new year and beyond.

Paige announced a collaboration with Microsoft to apply the power of artificial intelligence (AI) to digital pathology images to develop and deliver a new generation of clinical applications and computational biomarkers to transform cancer diagnosis and patient care.

AIRSUPRA™ (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.